The development of nucleoside antiviral drugs has become a global research hotspot. Dideoxynucleotides and their derivatives have attracted much attention as new nucleoside analogs. It has been found that such compounds have strong antiviral activity. For example, dideoxyguanosinic acid is well stabilized against biochemical enzymes and also shows antiviral activity. Many dideoxynucleotides and their derivatives inhibit HIV-1 reverse transcriptase, act as DNA polymerase inhibitors, or act as competitors for HIV-1 reverse transcriptase and DNA polymerase substrates. By intervening in the synthesis of viral cDNA and DNA, they ultimately play a role in treating AIDS or HBV infection. Dideoxynucleosides and their derivatives now occupy an unassailable position in the field of antiviral research. The development of dideoxynucleotide derivatives with more biological activities is necessary.
CD BioGlyco aims to develop nucleoside analogs with specialized structures for the research of different disease treatments, resistance to toxicity, and drug resistance. We design different pathways to minimize the production steps and time of the dideoxynucleotide derivative.
The structure of ddGTP is a nucleoside base shift, formed by chemically shifting the base to another position in the sugar ring. The normal glycosidic bond no longer exists in its structure, thus it has better chemical and enzymatic stability. We optimize the chemical production process of ddGTP to improve the product yield. At the same time, we also carry out enzyme kinetic studies on ddGTP by targeting viral DNA polymerase and HIV reverse transcriptase. Upon request, we study the mechanism of its antiviral action.
ddNTPs can be used in DNA sequencing as strand elongation inhibitors of DNA polymerase. ddNTPs are important for the detection of rare mutations. Besides ddGTP, we also provide ddATP, ddCTP, and ddTTP custom production services.
Fig.1 The structure of ddATP. (Wikipedia)
The phosphodiester bond on dideoxynucleotide analogs is quite different in conformation from normal oligonucleotides. It is found that dideoxynucleotides have antitumor and antiviral effects. The design and production of dideoxynucleotide derivatives is expected to discover new antiviral and antitumor drugs. We produce deoxynucleotide derivatives mainly by chemical and Bioenzymatic Methods. To produce various deoxynucleotide derivatives, we introduced protecting groups or structural modifications at different parts of nucleotides. We modify and transform various aspects of bases, ribose, and nucleoside bond conformation. The enzymatic method is green and has a single-product structure. The use of biological enzyme-catalyzed production will be the trend of future development. We also produce dideoxynucleotide derivatives with biological enzyme-catalyzed production, such as deoxynucleotidyl transferase.
Fig.2 Production process of dideoxynucleotide derivative. (CD BioGlyco)
CD BioGlyco has extensive expertise and large-scale production capacity for nucleoside analogs. With our extensive experience, we will excel in accomplishing various production challenges. In addition to dideoxynucleotide derivative, we also offer Adenosine Derivative and Nucleoside-based Adenine Derivative Production Services. Welcome to contact us for specific information on the production of dideoxynucleotide derivatives.
Reference
